Ignite Creation Date:
2024-05-06 @ 6:54 PM
Last Modification Date:
2024-10-26 @ 2:57 PM
Study NCT ID:
NCT05829356
Status:
COMPLETED
Last Update Posted:
2024-05-09
First Post:
2023-04-06
Brief Title:
Substudy 01 - Safety and Immunogenicity of One Monovalent Modified mRNA Vaccine Encoding Influenza Hemagglutinin With LNP in Adult Participants Aged 18 to 49 Years and 60 Years and Above
Sponsor:
Sanofi Pasteur a Sanofi Company
Organization:
Sanofi
Study Overview
Official Title:
A Phase I Parallel Randomized Active-controlled Multi-center Dose-escalation Study With Early Safety Data Reviews to Assess Safety and Immunogenicity of One Monovalent Modified Influenza mRNA Vaccine Encapsulated in LNP in Adults Aged 18 to 49 Years and 60 Years and Above
Status:
COMPLETED
Status Verified Date:
2024-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a Phase 1 parallel randomized active-controlled multi-center dose-esclation study with a Master Protocol design which will include several substudies that are developed to evaluate the safety and immunogenicity of different dose levels of modified messenger ribonucleic acid mRNA vaccines encoding full length hemagglutinin HA sequence of influenza virus encapsulated in lipid nanoparticles LNPs hereafter referred to as HA mRNA vaccines compared to controls The HA mRNA vaccine candidates and controls are presented in the substudy protocols
The aim is to generate clinical data across different substudies to provide learnings regarding the mRNA technology to support optimization of the mRNA platform including mRNA and LNP design and to support the decision of LNP and dose selection for future projects using mRNA technology
The purpose of this Substudy 01 is to evaluate the safety and immunogenicity of a single IM injection of up to 5 dose levels of a monovalent modified mRNA encoding the full-length HA sequence of ATasmania5032020 H3N2 influenza virus encapsulated in LNP hereafter referred to as H3 mRNA LNP administered as a single intramuscular IM injection in adults 18 to 49 years of age and 60 years of age and above compared to the following active control a quadrivalent recombinant influenza vaccine RIV4
The aim is to generate clinical data across different substudies to provide learnings regarding the mRNA technology to support optimization of the mRNA platform including mRNA and LNP design and to support the decision of LNP and dose selection for future projects using mRNA technology
The purpose of this Substudy 01 is to evaluate the safety and immunogenicity of a single IM injection of up to 5 dose levels of a monovalent modified mRNA encoding the full-length HA sequence of ATasmania5032020 H3N2 influenza virus encapsulated in LNP hereafter referred to as H3 mRNA LNP administered as a single intramuscular IM injection in adults 18 to 49 years of age and 60 years of age and above compared to the following active control a quadrivalent recombinant influenza vaccine RIV4
Detailed Description:
The study duration per participant will be approximately 6 months with 1 injection of one of the different HA mRNA vaccines or control for each substudy and a dose-escalation with sequential enrollment sentinel cohort followed by main cohort
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| U1111-1278-3835 | REGISTRY | ICTRP | None |